【摘要】：目的:檢測(cè)三陰性乳腺癌(triple negative breast cancer,TNBC)、非三陰性乳腺癌(non-triple negative breast cancer,NTNBC)組織中的p53、Ki-67、及E-cadherin蛋白表達(dá),探討三個(gè)指標(biāo)與TNBC臨床病理特征的關(guān)系,以及三種蛋白表達(dá)的相關(guān)性。并結(jié)合臨床隨訪資料,分析上述三種蛋白的表達(dá)與TNBC患者預(yù)后的關(guān)系。方法:采用免疫組織化學(xué)染色二步法分別檢測(cè)52例TNBC、52例NTNBC中p53、Ki-67、及E-cadherin蛋白表達(dá),分析其與TNBC患者預(yù)后的關(guān)系。結(jié)果:1.TNBC、NTNBC中p53陽(yáng)性表達(dá)率分別為67.3%、44.2%,TNBC組織中p53陽(yáng)性表達(dá)率高于NTNBC(χ2=5.613,P=0.018);在TNBC組織中,p53陽(yáng)性表達(dá)與組織學(xué)分級(jí)、腫瘤大小、TNM分期有關(guān)(均P0.05),但與患者淋巴結(jié)轉(zhuǎn)移、年齡、絕經(jīng)狀態(tài)無(wú)關(guān)(均P0.05);生存曲線顯示TNBC組織中p53陰性表達(dá)患者總體生存率顯著高于陽(yáng)性者(P0.05)。2.TNBC、NTNBC中Ki-67陽(yáng)性表達(dá)率分別為80.8%、61.5%,TNBC組織中Ki-67陽(yáng)性表達(dá)率高于NTNBC(χ2=4.685,P=0.030);在TNBC組織中,Ki-67表達(dá)陽(yáng)性與淋巴結(jié)轉(zhuǎn)移、TNM分期有關(guān)(均P0.05),但與患者腫瘤大小、年齡、組織學(xué)分級(jí)、絕經(jīng)狀態(tài)無(wú)關(guān)(均P0.05);生存曲線顯示TNBC組織中Ki-67陰性表達(dá)患者總體生存率顯著高于陽(yáng)性者(P0.05)。3.TNBC、NTNBC中E-cadherin陽(yáng)性表達(dá)率分別為26.9%、48.1%,TNBC組織中E-cadherin陽(yáng)性表達(dá)率低于NTNBC組織(χ2=4.964,P=0.026);在TNBC組織中,E-cadherin表達(dá)陽(yáng)性與腫瘤大小、淋巴結(jié)轉(zhuǎn)移、TNM分期有關(guān)(均P0.05),但與患者組織學(xué)分級(jí)、年齡、絕經(jīng)狀態(tài)無(wú)關(guān)(均P0.05);生存曲線顯示TNBC組織中E-cadherin陽(yáng)性表達(dá)患者總體生存率顯著高于陰性者(P0.05)。4.生存曲線顯示在TNBC組織中p53、Ki-67陰性及E-cadherin陽(yáng)性共表達(dá)患者的總體生存率顯著高于p53、Ki-67陽(yáng)性及E-cadherin陰性共表達(dá)患者(P0.05)。5.在TNBC組織中,p53、Ki-67陽(yáng)性表達(dá)呈正相關(guān)(r=0.388,P=0.004),p53、E-cadherin陽(yáng)性表達(dá)呈負(fù)相關(guān)(r=-0.686,P=0.000),Ki-67、E-cadherin陽(yáng)性表達(dá)呈負(fù)相關(guān)(r=-0.584,P=0.000)。6.Cox回歸分析單因素顯示,腫瘤大小、TNM分期、淋巴結(jié)轉(zhuǎn)移、p53、Ki-67及E-cadherin表達(dá)是影響三陰性乳腺癌患者總體生存率的顯著因素(均P0.05)。Cox回歸分析多因素顯示,p53、Ki-67及E-cadherin表達(dá)、淋巴結(jié)轉(zhuǎn)移是影響三陰性乳腺癌患者總體生存率的獨(dú)立預(yù)后因素(均P0.05)。結(jié)論:1.p53、Ki-67在三陰性乳腺癌組織中高表達(dá),其陽(yáng)性表達(dá)者預(yù)后差;E-cadherin在三陰性乳腺癌組織中低表達(dá),其陰性表達(dá)者預(yù)后差。2.p53、Ki-67及E-cadherin可能參與三陰性乳腺癌的發(fā)生、發(fā)展及浸潤(rùn)、轉(zhuǎn)移;聯(lián)合檢測(cè)p53、Ki-67及E-cadherin在三陰性乳腺癌中的表達(dá)可為患者提供分子治療的新靶點(diǎn)。
[Abstract]:Objective: to detect the expression of p53 Ki-67 and E-cadherin protein in (triple negative breast cancer,TNBC, non-triple-negative breast cancer (non-triple negative breast cancer,NTNBC), and to explore the relationship between the three markers and the clinicopathological features of TNBC. And the correlation between the expression of three proteins. The relationship between the expression of these three proteins and the prognosis of TNBC patients was analyzed. Methods: the expression of p53 Ki-67 and E-cadherin protein were detected by immunohistochemical staining in 52 cases of TNBC,52 with NTNBC. The relationship between the expression of p53 Ki-67 and the prognosis of TNBC was analyzed. Results: 1. The positive expression rate of p53 in TNBC was 67.3 and 44.2, respectively, which was higher than that in NTNBC (蠂 2 = 5.613). In TNBC, p53 positive expression was related to histological grade, tumor size and TNM stage (P0.05), but not to lymph node metastasis, age and menopausal status (P0.05). Survival curve showed that the overall survival rate of patients with p53 negative expression in TNBC was significantly higher than that of positive patients (P0.05). 2. The positive expression rate of Ki-67 in TNBCnTBC was 80.8% and 61.5%, respectively. The positive expression rate of Ki-67 in TNBC was higher than that in NTNBC (蠂 2 + 4.685% P0.030). In TNBC, the positive expression of Ki-67 was related to lymph node metastasis and TNM stage (P0.05), but not to tumor size, age, histological grade and menopausal status (P0.05). Survival curve showed that the overall survival rate of patients with negative expression of Ki-67 in TNBC was significantly higher than that of patients with positive expression (P0.05). 3. The positive expression rate of E-cadherin in NTNBC was 26.9% and 48.1%, respectively. The positive expression rate of E-cadherin in TNBC was lower than that in NTNBC (蠂 2 / 4.964). In TNBC, the positive expression of E-cadherin was related to tumor size, lymph node metastasis and TNM stage (P0.05), but not related to histological grade, age and menopausal status (P0.05). Survival curve showed that the overall survival rate of E-cadherin positive expression patients in TNBC was significantly higher than that of negative patients (P0.05). Survival curve showed that the overall survival rate of patients with p53 Ki-67 and E-cadherin positive co-expression in TNBC was significantly higher than that in p53 Ki-67 positive and E-cadherin negative co-expression (P0.05). In TNBC, the positive expression of p53 Ki-67 was positively correlated with that of p538, E-cadherin (r-0.686) and Ki-67,E-cadherin (r-0.584), and the expression of E-cadherin was negatively correlated with that of p53- 0.686, and that of Ki-67,E-cadherin was negatively correlated with that of p53-p538, E-cadherin and Ki-67,E-cadherin (r-0.584, r = 0.584), respectively. 6.Cox regression analysis showed that the tumor size, TNM stage, lymph node metastasis, p53, p53, The expression of Ki-67 and E-cadherin was a significant factor influencing the overall survival rate of patients with triple-negative breast cancer (P0.05). Cox regression analysis showed that the expression of p53 Ki-67 and E-cadherin was significant in patients with breast cancer. Lymph node metastasis was an independent prognostic factor for the overall survival rate of triple negative breast cancer patients (P0.05). Conclusion: 1. The expression of p53 Ki-67 is high in tri-negative breast cancer, and the prognosis of the patients with positive expression is poor; The prognosis of patients with low expression of E-cadherin in tri-negative breast cancer is poor. 2.p53 Ki-67 and E-cadherin may be involved in the occurrence, development, invasion and metastasis of tri-negative breast cancer. Combined detection of p53 Ki-67 and E-cadherin in tri-negative breast cancer may provide a new target for molecular therapy.
【學(xué)位授予單位】：江蘇大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 傅晨薇 ,郎景和;SERUM SOLUBLE E-CADHERIN LEVEL IN PATIENTS WITH ENDOMETRIOSIS[J];Chinese Medical Sciences Journal;2002年02期

2 夏紅強(qiáng);E-cadherin在腫瘤組織的檢測(cè)及意義[J];臨床腫瘤學(xué)雜志;2003年06期

3 ;Expression of TGF-β1,Snail,E-cadherin and N-cadherin in Gastric Cancer and Its Significance[J];Chinese Journal of Clinical Oncology;2007年06期

4 熊小蔚;崔明;;T-cadherin與腫瘤[J];醫(yī)學(xué)綜述;2010年08期

5 ;E－Cadherin在膀胱乳頭狀移行細(xì)胞癌的表達(dá)[J];國(guó)外醫(yī)學(xué)(生理、病理科學(xué)與臨床分冊(cè));1996年02期

6 張文軍,張志謙,林仲翔,王耐勤,胡穎;Correlation between expression of cadherin and gap junctional communication in human lung carcinoma cells[J];Science in China(Series C:Life Sciences);1998年04期

7 ;The expression of N-cadherin/catenins/actin complex in human lung normal and carcinoma cells[J];Chinese Science Bulletin;1998年09期

8 ;Quantitative analysis of E-cadherin expression and clinicopathologic evaluation in gastric cancer[J];Chinese Medical Journal;1998年01期

9 Ge-Liang Liu;Han-Jie Yang;Tian Liu;Yun-Zhao Lin;;Expression and significance of E-cadherin,N-cadherin,transforming growth factor-β1 and Twist in prostate cancer[J];Asian Pacific Journal of Tropical Medicine;2014年01期

10 王曦,吳人亮,郝天玲,陳芳;Effects of Cigarette Smoke Extract on E-cadherin Expression in Cultured Airway Epithelial Cells[J];Journal of Tongji Medical University;2000年01期

相關(guān)會(huì)議論文 前10條

1 ;Core Fucosylation Regulates E-cadherin Binding Affinity in Human Lung Cancer Cells[A];2008年全國(guó)生物化學(xué)與分子生物學(xué)學(xué)術(shù)大會(huì)論文摘要[C];2008年

2 ;Epigenetic regulation of E-cadherin in HBV associate human Hepatocellular carcinoma[A];江蘇省遺傳學(xué)會(huì)第八屆會(huì)員代表大會(huì)暨學(xué)術(shù)研討會(huì)論文集[C];2010年

3 王冰晶;張志謙;;癌細(xì)胞cadherin亞型轉(zhuǎn)變及其分子機(jī)制[A];中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)2005年學(xué)術(shù)大會(huì)、青年學(xué)術(shù)研討會(huì)論文摘要集[C];2005年

4 ;Suppressed survival and proliferation of ovarian cancer cells by repressed MEK-ERK activation via knocking-down of E-cadherin[A];中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)第七屆全國(guó)中青年腫瘤學(xué)術(shù)會(huì)議——中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)“中華腫瘤 明日之星”大型評(píng)選活動(dòng)暨中青年委員全國(guó)遴選論文匯編[C];2011年

5 ;N-cadherin:a potential receptor of GDNF[A];Proceedings of the 8th Biennial Conference of the Chinese Society for Neuroscience[C];2009年

6 Zhiyang Xu;Dechang Li;Baohua Ji;;Quantification of the stiffness and strength of cadherin ectodomain binding with different ions[A];北京力學(xué)會(huì)第20屆學(xué)術(shù)年會(huì)論文集[C];2014年

7 賈文亮;張慶瑜;;關(guān)于E-cadherin在胃癌和肺癌中表達(dá)情況的研究[A];天津市生物醫(yī)學(xué)工程學(xué)會(huì)第三十三屆學(xué)術(shù)年會(huì)論文集[C];2013年

8 烏新春;倪志超;段昕所;宋有鑫;;綠色熒光蛋白標(biāo)記的T-cadherin基因穩(wěn)定轉(zhuǎn)染黑素瘤細(xì)胞株的建立[A];第五屆全國(guó)中醫(yī)藥免疫學(xué)術(shù)研討會(huì)——暨環(huán)境·免疫與腫瘤防治綜合交叉會(huì)議論文匯編[C];2009年

9 ;Manipulation of N-cadherin level and function through different methods results in distinct functional changes in hippocampal neurons[A];Proceedings of the 7th Biennial Meeting and the 5th Congress of the Chinese Society for Neuroscience[C];2007年

10 張憲真;陳隨芹;耿秀東;;N-Cadherin與E-Cadherin在非小細(xì)胞肺癌中的表達(dá)及相關(guān)性研究[A];中國(guó)腫瘤內(nèi)科進(jìn)展 中國(guó)腫瘤醫(yī)師教育（2014）[C];2014年

相關(guān)博士學(xué)位論文 前10條

1 楊俊俊;Rab5 GTPase介導(dǎo)的VE-cadherin內(nèi)吞調(diào)控肺微血管內(nèi)皮細(xì)胞屏障功能的機(jī)制[D];第三軍醫(yī)大學(xué);2015年

2 張紅燕;STAT3/ZEB1/E-cadherin信號(hào)軸在食管鱗癌上皮間質(zhì)轉(zhuǎn)化中的作用及機(jī)制研究[D];鄭州大學(xué);2016年

3 陶祥;SNAI2—E-cadherin軸在LRIG1調(diào)節(jié)人腦膠質(zhì)瘤細(xì)胞侵襲和轉(zhuǎn)移中的作用研究[D];武漢大學(xué);2016年

4 王唯一;雙氫青蒿素對(duì)喉癌干細(xì)胞侵襲和轉(zhuǎn)移的影響及其相關(guān)機(jī)制研究[D];河北醫(yī)科大學(xué);2017年

5 宋小珍;Par3-aPKC與Vangl2相互作用并參與調(diào)節(jié)E-cadherin-based粘附連接和管腔化形成[D];北京協(xié)和醫(yī)學(xué)院;2017年

6 馬福哲;12-脂氧化酶對(duì)糖尿病腎病腎小球P-cadherin表達(dá)的影響及其機(jī)制研究[D];吉林大學(xué);2017年

7 瞿金妙;E-cadherin，，CD44和MSH2相關(guān)的列線圖預(yù)測(cè)Ⅱ和Ⅲ期結(jié)直腸癌預(yù)后[D];南方醫(yī)科大學(xué);2017年

8 馮海燕;鼻咽癌中R-cadherin基因的表觀沉默機(jī)制及抑癌功能研究[D];廣西醫(yī)科大學(xué);2010年

9 黎景佳;E-cadherin在喉鱗狀細(xì)胞癌中的表達(dá)及其與腫瘤侵襲轉(zhuǎn)移的關(guān)系[D];中南大學(xué);2010年

10 吳揚(yáng);VE-cadherin重組腺病毒偶聯(lián)氧化型甘露聚糖抗腫瘤實(shí)驗(yàn)研究[D];四川大學(xué);2005年

相關(guān)碩士學(xué)位論文 前10條

1 衷燦梅;12-脂氧合酶通過(guò)上皮間質(zhì)轉(zhuǎn)化促進(jìn)胃癌侵襲轉(zhuǎn)移的機(jī)制研究[D];福建醫(yī)科大學(xué);2015年

2 高玉梅;探索N-cadherin在卵巢癌發(fā)生和進(jìn)展中的作用及意義[D];石河子大學(xué);2015年

3 林路;E-cadherin,β-catenin,N-cadherin在漿液性卵巢癌中的表達(dá)及意義[D];安徽醫(yī)科大學(xué);2015年

4 辛明;Galectin-3通過(guò)EGFR介導(dǎo)調(diào)控腫瘤細(xì)胞E-cadherin表達(dá)的機(jī)制研究[D];山東大學(xué);2015年

5 孟梅;VE-cadherin對(duì)血管穩(wěn)態(tài)的作用及調(diào)控機(jī)制[D];蘇州大學(xué);2015年

6 汪威;丙泊酚對(duì)荷瘤大鼠MADB106腫瘤細(xì)胞肺轉(zhuǎn)移及E-cadherin和β-catenin的影響[D];南方醫(yī)科大學(xué);2015年

7 孫琳;ALCAM、E-cadherin和β-catenin在甲狀腺乳頭狀癌中的表達(dá)及意義[D];河北醫(yī)科大學(xué);2014年

8 于海峰;FOXQ1和E-cadherin在食管鱗狀細(xì)胞癌中的表達(dá)及臨床意義[D];天津醫(yī)科大學(xué);2015年

9 何宏月;EMT相關(guān)蛋白E-cadherin、N-cadherin、Snail和Slug在子宮內(nèi)膜異位癥中的表達(dá)及意義[D];天津醫(yī)科大學(xué);2015年

10 劉超;EMX2和E-cadherin在食管鱗癌中的表達(dá)及臨床病理意義[D];天津醫(yī)科大學(xué);2015年

本文編號(hào)：2385658